London, United Kingdom
With expertise in unquoted and life science biomedical companies, Abingworth is a well-established venture capital firm. For the past 15 years, Abingworth has invested in more than 80 emerging businesses in the life science and medical field, across both the US and Europe. The firm has a track record of backing successful ventures that have either gone public or been acquired by leading industry players.
107
Total Investments
69
Portfolio Companies
-
Exits
5
Industries
General Information
Industries
Biotechnology, Finance +3
Funding Stage
Series A +1
Company Overview
Investment Criteria
Investment Thesis
•••••• •••••• ••••••
About Abingworth
Recent Investments (107)
View All| Company | Stage | Amount | Date |
|---|---|---|---|
| Late Vc | •••••• | Nov 2025 | |
| Series C | •••••• | Aug 2025 | |
| Series C | •••••• | Apr 2025 | |
| Series C | •••••• | Apr 2025 | |
| Series A | •••••• | Jul 2024 | |
•••• ••••
|
Series B | •••••• | Jun 2024 |
|
•••• ••••
|
Post Ipo Equity | •••••• | Mar 2024 |
|
•••• ••••
|
Post Ipo Equity | •••••• | Feb 2024 |
|
•••• ••••
|
IPO | •••••• | Nov 2023 |
|
•••• ••••
|
Series B | •••••• | Oct 2023 |
All startup & investor data, one platform.
Filter investors by stage, sector, and geography. Compare portfolios side by side. Spot market signals before anyone else.
